Hematology

Cardiology   

Questions discussed in this category



In FRAIL-AF, switching VKA therapy to a NOAC was associated with higher risk of bleeding in elderly, frail patients. 

In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.

Would you bridge with enoxaparin 0.7 mg/kg/day in an ESKD patient, as described in a previous retrospective study (Pon et al., PMID: 24718051)?

E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

Please comment on temperature recommendations and role of exchange transfusion. 

How do you approach secondary stroke prevention for patients with ischemic stroke, atrial fibrillation, and signs of cerebral amyloid angiopathy/micro...

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...


Papers discussed in this category


The New England journal of medicine, 2015-12-17

Blood, 2022 Jul 14

Leukemia, 2021 Apr 27

J Am Coll Cardiol, 2019 Oct 01

Circulation, 2012-09-25

BMJ, 2021 Jun 09

Haematologica, 2010-07

The American journal of medicine, 1997-01

Haematologica, 2019 Aug 14

Circulation, 2023 Aug 27